CRISPR/Cas9 knockout of TopBP1 shifts Bax/Bcl-2 balance, boosting apoptosis in MCF7 breast cancer cells
Background
Breast cancer (BC) remains the most prevalent cancer among women and a leading cause of cancer-related deaths globally, highlighting an urgent need for innovative therapeutic strategies. Current treatments often face challenges like resistance, necessitating novel approaches that target fundamental cellular processes. The TopBP1 (DNA Topoisomerase II Binding Protein 1) gene is a critical regulator involved in DNA damage response and cell cycle regulation, and its overexpression has been linked to cancer progression and chemoresistance. This study explores TopBP1 as a potential therapeutic target to induce cell death in breast cancer.
Study Design
Researchers employed the CRISPR/Cas9 gene-editing system to target and knock out the TopBP1 gene in MCF7 breast cancer cells. A pair of specific guide RNAs (gRNAs) was designed to induce the deletion of exon 4 within the TopBP1 gene. These gRNAs were transfected into the MCF7 cell line. The success of the genomic editing was rigorously validated using PCR and Sanger sequencing to confirm the exon 4 deletion. Subsequent analyses, including real-time PCR and Western blotting, were performed to evaluate the downstream effects of TopBP1 knockout on the expression levels of key apoptotic genes.
Results
The CRISPR/Cas9 system successfully achieved the targeted knockout of TopBP1 exon 4 in MCF7 breast cancer cells, with genomic editing confirmed by PCR and Sanger sequencing. This genetic modification led to a reduction in overall TopBP1 expression. Subsequent real-time PCR analysis revealed a significant increase in the expression of the pro-apoptotic gene Bax in the TopBP1 knockout cells. Concurrently, there was a notable decrease in the expression of the anti-apoptotic gene Bcl-2 compared to control cells. These changes in the Bax/Bcl-2 ratio are indicative of a shift towards a pro-apoptotic cellular state. The findings strongly support the hypothesis that targeting TopBP1 can play a critical role in promoting cell death in breast cancer. This suggests that MCF7 cells may become more sensitive to apoptosis following TopBP1 knockout. Overall, the results demonstrate the potential of TopBP1 as a novel therapeutic target.
Key Findings
- CRISPR/Cas9 successfully knocked out
TopBP1exon 4 inMCF7breast cancer cells. - Knockout of
TopBP1led to a significant increase inBaxgene expression. - Knockout of
TopBP1resulted in a decrease inBcl-2gene expression. - The altered
Bax/Bcl-2ratio indicates enhanced apoptotic activity inTopBP1-deficient cells.
Why It Matters
This study provides compelling in-vitro evidence that targeting TopBP1 via CRISPR/Cas9 gene editing can effectively promote apoptosis in breast cancer cells by modulating the Bax/Bcl-2 balance. The practical takeaway is that inhibiting TopBP1 could sensitize breast cancer cells to programmed cell death, potentially overcoming resistance mechanisms. For future clinical translation, this research opens avenues for developing novel gene therapies or small molecule inhibitors that mimic the effects of TopBP1 knockout. While direct human application of CRISPR/Cas9 for this purpose is still distant, these findings lay foundational groundwork for new therapeutic strategies that could enhance the efficacy of existing breast cancer treatments or provide alternatives for resistant cases. This mechanism could be explored in combination with other pro-apoptotic agents.
crispr-cas9
topbp1
breast-cancer
apoptosis
mcf7
in-vitro